Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

10.1007/s10147-021-01869-0

Saved in:
Bibliographic Details
Main Authors: Chang, Gee-Chen, Lam, David Chi-Leung, Tsai, Chun-Ming, Chen, Yuh-Min, Shih, Jin-Yuan, Aggarwal, Shyam, Wang, Shuhang, Kim, Sang-We, Kim, Young-Chul, Wahid, Ibrahim, Li, Rubi, Lim, Darren Wan-Teck, Sriuranpong, Virote, Chan, Raymond Tsz-Tong, Lorence, Robert M, Carriere, Philippe, Raabe, Christina, Cseh, Agnieszka, Park, Keunchil
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Article
Language:English
Published: SPRINGER JAPAN KK 2022
Subjects:
Science & Technology
Life Sciences & Biomedicine
Oncology
Afatinib
HER2 mutations
Lung cancer
Named patient use
NSCLC
Uncommon EGFR mutations
Online Access:https://scholarbank.nus.edu.sg/handle/10635/218517
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Language: English

Similar Items

Similar Items